Business Standard
Notification Icon
userprofile IconSearch

Abbott India

Abbott launches leadless pacemaker in India for slow heart rhythms

Drug firm Abbott has launched a pacemaker in India for the treatment of patients with slow heart rhythms. Abbott has introduced AVEIR VR single-chamber ventricular leadless pacemaker which has been approved by the Central Drugs Standard Control Organisation, the company said in a statement on Friday. The product has also been approved by the US Food and Drug Administration (USFDA). "The AVEIR VR leadless pacemaker was designed to make the implantation and retrieval processes as seamless as possible for physicians and provide improvements over existing options," said Ajay Singh Chauhan, General Manager for Abbott's Cardiac Rhythm Management business in India, Southeast Asia, HK, Taiwan & Korea. People who experience slower-than-normal heart rhythm may receive a pacemaker to deliver pulses of electricity to trigger the heart to beat properly. Balbir Singh, Chairman Cardiology, Max Superspeciality Hospital said, "Leadless pacemakers address known complications associated with ...

Abbott launches leadless pacemaker in India for slow heart rhythms
Updated On : 22 Nov 2024 | 6:55 PM IST

Abbott India recalls Pentids antibiotic batches over packaging issues

Pentids are widely prescribed for treating bacterial infections of the respiratory tract, throat, lungs, nose, skin, and sexually transmitted diseases like syphilis

Abbott India recalls Pentids antibiotic batches over packaging issues
Updated On : 28 Aug 2024 | 5:06 PM IST

Here's why Abbott India stock price surged 5% on August 8; details here

The uptick in the pharma company's stock price came after it posted a healthy set of numbers in the June quarter of financial year 2025 (Q1FY25).

Here's why Abbott India stock price surged 5% on August 8; details here
Updated On : 08 Aug 2024 | 12:39 PM IST

Abbott India Q1 results: PAT rises 13% to Rs 328 cr, income at Rs 1,625 cr

Drug firm Abbott India on Wednesday said its net profit increased by 13 per cent year on year to Rs 328 crore for the first quarter ended June 30, 2024. The company reported a net profit of Rs 290 crore in the April-June quarter of last fiscal. Total income rose to Rs 1,625 crore for the period under review as against Rs 1,535 crore in the June quarter of FY24, Abbott India said in a regulatory filing. Shares of the company on Wednesday ended 1.29 per cent up at Rs 28,159.95 apiece on the BSE.

Abbott India Q1 results: PAT rises 13% to Rs 328 cr, income at Rs 1,625 cr
Updated On : 07 Aug 2024 | 10:10 PM IST

Abbott India rises 4% on strong Q4 performance

Abbott India's profit jumped 24.1 per cent to Rs 287.1 crore in the March quarter of FY24 (Q4FY24), from Rs 231.4 crore in the March quarter of FY23 (Q4FY23)

Abbott India rises 4% on strong Q4 performance
Updated On : 10 May 2024 | 10:26 AM IST

Abbott India Q4 results: Profit rises 24% to Rs 287 cr, revenue up 7%

The drugmaker's revenue from operations increased to Rs 1,439 crore, a 7 per cent increase from the Rs 1,343 crore recorded in Q4 FY23

Abbott India Q4 results: Profit rises 24% to Rs 287 cr, revenue up 7%
Updated On : 09 May 2024 | 8:04 PM IST

How to trade F&O stocks with high rollovers in May; check key levels here

Technical outlook on stocks with high rollover to May series: Keep a tab on these key support and resistance levels while trading in these F&O stocks.

How to trade F&O stocks with high rollovers in May; check key levels here
Updated On : 26 Apr 2024 | 12:01 PM IST

Strong portfolio, slew of launches to help Abbott India outperform

The company's Year-on-Year revenue growth of 8.3% exceeded expectations and its top line was aided by a product mix led by therapies

Strong portfolio, slew of launches to help Abbott India outperform
Updated On : 08 Mar 2024 | 10:35 PM IST

Portfolio, new launches to help pharma company Abbott India's stock

Firm's revenues were in line with estimates and operational parameters better than expected

Portfolio, new launches to help pharma company Abbott India's stock
Updated On : 29 Feb 2024 | 1:47 PM IST

Abbott Q3 results: Profit rises 26% to Rs 311 cr on strong demand

The company, which makes popular antacid medicine Digene, said its profit rose to 3.11 billion rupees ($37.5 million) from 2.47 billion rupees a year earlier

Abbott Q3 results: Profit rises 26% to Rs 311 cr on strong demand
Updated On : 01 Feb 2024 | 6:48 PM IST

Abbott India warns of laxatives shortage in tussle with Goa regulator

The two laxative brands together have estimated annual sales of $70 million in India, healthcare data firm Pharmarack says

Abbott India warns of laxatives shortage in tussle with Goa regulator
Updated On : 22 Sep 2023 | 7:21 PM IST

Goa state warns Abbott India on antacid Digene license suspension

The state authorities have given Abbott seven days to respond to the notice to defend its position

Goa state warns Abbott India on antacid Digene license suspension
Updated On : 14 Sep 2023 | 5:37 PM IST

Abbott India recalls batches of Antacid Digene gel

In its letter, the DCGI warned that Digene may be unsafe and its use may result in adverse reaction

Abbott India recalls batches of Antacid Digene gel
Updated On : 07 Sep 2023 | 4:27 PM IST

Abbott recalls antacid Digene Gel made in Goa after consumer complaints

India's drugs regulator issues advisory against use; company says there is no 'health concern'

Abbott recalls antacid Digene Gel made in Goa after consumer complaints
Updated On : 07 Sep 2023 | 2:36 PM IST

Abbott India posts 41% rise in Q1 profit at Rs 29 crore on strong sales

The company has reported a double-digit growth in its revenue for the past three quarters, led by falling operating expenses and steady sales

Abbott India posts 41% rise in Q1 profit at Rs 29 crore on strong sales
Updated On : 09 Aug 2023 | 8:06 PM IST

Stocks to watch: Wipro, HUL, Axis Bank, Bajaj Finance, Tata Power, Abbott

Stocks to watch today: From Hindustan Unilever to Wipro, here are top stocks to watch in Thursday's trading session

Stocks to watch: Wipro, HUL, Axis Bank, Bajaj Finance, Tata Power, Abbott
Updated On : 27 Apr 2023 | 7:51 AM IST

5 mid-cap stocks hit crucial peaks, enter next bull run; Do you own any?

These 5 mid-cap stocks may rise up to 20 per cent, as technical charts reveal positive breakouts

5 mid-cap stocks hit crucial peaks, enter next bull run; Do you own any?
Updated On : 10 Apr 2023 | 12:31 PM IST

Key brands, new launches to sustain Abbott India's outperformance

Margins to remain healthy on the back of cost-saving measures

Key brands, new launches to sustain Abbott India's outperformance
Updated On : 14 Mar 2023 | 11:07 PM IST

Measuring worth: Front-row seats to high return-on-equity stocks

A portfolio of richly valued RoE stocks is expected to outperform the broader market over the longer term.

Measuring worth: Front-row seats to high return-on-equity stocks
Updated On : 09 Nov 2022 | 12:05 AM IST

Core brands, new launches to help Abbott India stock outperform: Analysts

Analysts expect double-digit growth for pharma major even if Q1 disappointed

Core brands, new launches to help Abbott India stock outperform: Analysts
Updated On : 14 Sep 2022 | 10:45 PM IST